Every GLP-1 sold in the United States is getting a new warning on its label, and this one is about your eyes. Also on the rundown: a glucagon-based obesity drug clears a big heart-safety test, and new research shows what happened when state Medicaid programs stopped paying for weight-loss GLP-1s. You're listening to GLP-1 Daily on Tuesday, November 10. We start at the FDA.
Gabrielle Masson, writing in BioSpace:
The class-wide label change will involve adding a mention of non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that causes optic nerve swelling and can lead to blindness, often in one eye. With cases of NAION reported for all currently marketed GLP-1s, the FDA has concluded that the drug class is associated with a potentially higher risk of developing the condition and ordered all GLP-1 makers to update their labeling, according to a Monday release.
NAION gets called a stroke of the eye. Blood supply to the optic nerve is interrupted, and the vision loss can be permanent. The FDA's order, announced Monday, covers twelve drugs, including Wegovy, Ozempic, Zepbound, Mounjaro and the Foundayo pill. Here's the evidence. The FDA pooled 126 clinical trials with more than 78,000 people on a GLP-1 and found 15 probable cases: 10 on GLP-1s, five on placebo. That's 6.4 cases per 100,000 patient-years on the drugs versus 3.8 on comparators. So rare, but not zero. The FDA's real-world data were mixed, and it hasn't found a mechanism. This is a Warnings and Precautions update, not a limit on who can take these drugs. Some context. Europe's regulator called NAION a very rare side effect of semaglutide in June 2025. Biobook Media notes U.S. patients have sued, alleging vision loss, and Lilly and Novo deny a link. Speaking as someone on one of these drugs: coverage of the FDA's communication says to seek medical attention right away if your vision changes. If you have other eye risk factors, raise this with your prescriber. Don't stop a medication over a headline.
Erik Swain, writing in Healio, with a perspective from Dr. Ashish Sarraju:
However, this was not a trial that studied survodutide for superiority, so we cannot tell patients that this is going to improve their CV risk.
The drug is survodutide, from Boehringer Ingelheim and Zealand. It acts on both glucagon and GLP-1 receptors, and it isn't approved yet. The worry was the glucagon side, because early testing showed heart rates going up. The trial, SYNCHRONIZE-CVOT, was presented Monday at the American Heart Association meeting in Chicago and published in The Lancet. About 5,500 adults with obesity or overweight plus heart disease, kidney disease or other risk factors. On heart attack, stroke, heart failure events and cardiovascular death, survodutide was noninferior to placebo. Translation: no sign of excess harm. Boehringer funded it. Then there's tolerability. BioSpace reports roughly one in five people on survodutide dropped out, mostly over stomach side effects, versus 1.9 percent on placebo. Zealand blames a rigid dose-escalation protocol. That's the company's explanation, and newer trials will test it. William Blair analysts expect approval but think use will mostly be confined to patients with liver-related risk. If you have heart disease, this changes nothing today. Some drugs in the class already have proven heart benefit, and that's the conversation to have with your cardiologist.
From PeptideDDP, a peptide-industry news site, summarizing a new study:
A quasi-experimental study published in Cureus on November 6, 2026, reports that when five state Medicaid programs withdrew coverage of GLP-1 receptor agonists for obesity in late 2025 and January 2026, reimbursed dispensing of obesity-indicated GLP-1 drugs fell 84.7% relative to states that kept coverage.
We were last on Medicaid on November 3, with advocates pushing Ohio to start covering these drugs. This is the other side of that ledger: what happens when coverage goes away. The paper, out Friday, compared five states that withdrew coverage with 12 that kept it. In the four states that cut coverage on January 1, reimbursed prescriptions fell from about 661,000 in one quarter to about 135,000 the next. And almost none of that moved to older weight-loss drugs. Diabetes prescriptions held steady, because states generally must cover those; weight loss is one of the few categories they can drop. California ended coverage to cut pharmacy spending. That's a budget decision with names on it. Caveats. It counts prescriptions, not people, so it can't say who stopped treatment and who moved to cash pay or other insurance. The newest quarter is provisional. And PeptideDDP's write-up doesn't name the study's funders. If your state plan changed, ask your prescriber's office whether an existing authorization carries over, and what your options are before a refill lapses.
If this episode helped you make sense of a label change you'll be hearing about all week, a quick rating or review in your podcast app helps other patients find GLP-1 Daily.
We report the news; your own treatment decisions belong with your prescriber. GLP-1 Daily comes to you from Lantern Podcasts, and we'll be back tomorrow, Wednesday.